Research has shown that the neurotransmitter acetylcholine (Ach) is less expressed in the brain of Alzheimer’s patients when compared to normal patient’s levels. It is proposed that this decrease stems from the hydrolysis of Ach by the enzyme acetylcholinesterase (AChE). As a result, acetylcholinesterase inhibitors have been identified to be a viable option as a disease-modifying treatment for cognitive deficits of patients with Alzheimer’s disease. Flavonoids, natural products that exhibit acetylcholinesterase inhibitory activity, can potentially serve as promising leads for the treatment of Alzheimer’s disease. Through the use of rational drug design, this research project will advance the synthesis of novel flavonoid derivatives that incorporate nitrogen-containing fused heterocyclic rings, which were identified through SAR as crucial structural elements, in an effort to propose an effective treatment of Alzheimer’s disease.

Synthesis of novel flavonoid derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.